Abstract
Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Current Drug Safety
Title:Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects
Volume: 9 Issue: 2
Author(s): George F. Lasker, Fikret Halis and Ahmet Gokce
Affiliation:
Keywords: Erectile dysfunction, PE treatment, premature ejaculation, selective serotonin reuptake inhibitor, SSRI.
Abstract: Premature ejaculation is one of the most prevalent sexual disorders affecting men today. The lack of approved therapies has resulted in the prescription of many ‘off-label’ treatments to manage the condition. Selective serotonin reuptake inhibitors have an interesting side effect of prolonging ejaculatory latency. Consequently, these agents are often considered a first line treatment for patients suffering from premature ejaculation. Erectile dysfunction is another common side effect reported by men treated with selective serotonin reuptake inhibitors. Nitric oxide is the primary mediator of erectile function. Preclinical studies have provided evidence that selective serotonin reuptake inhibitors decrease nitric oxide bioavailability. This invited mini-review aims to examine the physiology of the erectile and ejaculatory responses, discuss the indicated and ‘off-label’ clinical utility of selective serotonin reuptake inhibitors, and to summarize evidence from basic science and clinical studies pertaining to mechanisms of how selective serotonin reuptake inhibitor therapy modifies ejaculatory and erectile function.
Export Options
About this article
Cite this article as:
Lasker F. George, Halis Fikret and Gokce Ahmet, Selective Serotonin Reuptake Inhibitors for Premature Ejaculation: Review of Erectile and Ejaculatory Side Effects, Current Drug Safety 2014; 9 (2) . https://dx.doi.org/10.2174/1574886309666140120095846
DOI https://dx.doi.org/10.2174/1574886309666140120095846 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regulation of Stem Cell-Based Research in India in Comparison with the US, EU and other Asian Countries: Current Issues and Future Perspectives
Current Stem Cell Research & Therapy Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology Editorial (Thematic Issues: New Developments in the Medicinal Chemistry of Some Azoles)
Current Topics in Medicinal Chemistry Fatty Acids and Obesity
Current Pharmaceutical Design Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Management of Blood Pressure and Heart Rate in Patients with Acute Stroke
Current Pharmaceutical Design Orekhov`s Method: Reassessment of In vitro Lipid Uptake Assays
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Nutritional Overview on the Management of Type 2 Diabetes and the Prevention of its Complications
Current Diabetes Reviews The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Association of flavonoid-rich foods and statins in the management of hypercholesterolemia: a dangerous or helpful combination?
Current Drug Metabolism Editorial (Thematic Issue: Protection, Repair and Regeneration of Achybreaky Heart)
Current Drug Targets Food-Derived Peptides and Intestinal Functions
Current Pharmaceutical Design Behcets Syndrome: Literature Review
Current Rheumatology Reviews Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Diabetic Vascular Dysfunction
Current Vascular Pharmacology Novel, Unifying Phagomimetic Mechanism of Vancomycin Therapeutic Action and Toxicity: Polyphenol, Electron Transfer and Reactive Oxygen Species
Anti-Infective Agents in Medicinal Chemistry Markers of Systemic Inflammation in Obstructive Sleep Apnea Syndrome
Current Respiratory Medicine Reviews Multitarget Network Strategies to Influence Memory and Forgetting: The Ras/Mapk Pathway as a Novel Option
Mini-Reviews in Medicinal Chemistry Apoptosis: Potential Therapeutic Targets for New Drug Discovery
Current Medicinal Chemistry The Role of Molecular Imaging in the Assessment of Cardiac Amyloidosis: State-of-the-Art
Current Radiopharmaceuticals The C242T CYBA Polymorphism as a Major Determinant of NADPH Oxidase Activity in Patients with Cardiovascular Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry